Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma

Medicine & Life Sciences

• ibritumomab tiuxetan 100%
• Radioimmunotherapy 84%
• B-Cell Lymphoma 62%
• Non-Hodgkin's Lymphoma 57%
• Rituximab 42%
• Yttrium-90 12%
• Cold Temperature 7%
• Anti-Idiotypic Antibodies 7%
• Appointments and Schedules 7%
• Indium-111 6%
• Immunoconjugates 5%
• Pentetic Acid 5%
• Clinical Trials 5%
• Chelating Agents 4%
• Platelet Count 4%
• Immunotherapy 3%
• Intercellular Signaling Peptides and Proteins 3%
• Stem Cells 3%
• Monoclonal Antibodies 3%
• Antibodies 2%
• Therapeutics 1%

Chemical Compounds

• Dosimetry 82%
• Growth Factor 71%
• Radioisotope 66%
• Refractory 62%
• Chelating Agent 58%
• Dose 46%
• Time 21%